-- Data support ongoing development of antibody-drug conjugate (ADC) program targeting HER3-expressing cancers –-- On-track to nominate development candidate in 2024 --BOSTON, March 5, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical need, today announced that it will present preclinical proof-of-concept data for it ...